Blood Test to predict response to treatments

ACOBIOM's objective is to commercialize innovative medical Diagnostics that can predict a patient's individual response to certain treatments. To develop and validate these diagnostic tests, the company is seeking financial partners interested in the perspectives and the benefits of Precision Medicine.

ACOBIOM (Montpellier, France) develops innovative Medical Diagnostics that can predict the therapeutical responses. The company is currently involved in the development of several Diagnostic Tests in Precision Medicine focused on Oncology and Neurology
These Diagnostics are non invasive and can be performed from a simple blood sample. These tests are based on the simultaneous measurement of a combination of several patented markers and data analysis using a proprietary algorithm. They have been developing for routine uses on platforms already used in central labs and clinical centres.

ACOBIOM’s Diagnostics (cf pipeline below) are the results of the combination of a 18-year technical know-how in genomics & transcriptomics, of Bioinformatics tools dedicated to genomic & transcriptomic data analysis, of a proprietary database containg 27,000 RNA-Seq profiles (Big Data), and of a unique scientific expertise in the analysis of genomic & transcriptomic data.

Pipeline EN 20171207

ACOBIOM’s business positions the company in several growing markets that generate important revenues as the Companion Diagnostics in Oncology, market that has been estimated at US$ 3.5B in 2016, and should grow to US$ 13.6B in 2025 (source : Transparency Market Research).

An Executive Summary (in French) can be downloaded by the financial partners interested in the ambition and the objectives of ACOBIOM to commercialize  innovative medical Diagnostics to improve treatments in oncology and neurology.

To obtain more information about ACOBIOM (#Acobiom_Biotech) and its perspectives (#PrecisionMedecine), please contact Philippe Outrebon (, T: +33(0)467 419 748)